RiverVest Venture Partners — 2016 Investments
3 investments dated 2016 · listed companies and verified rows first · show all
AnTolRxantolrx.cominSeries A · Sep 2016 · $4M
AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders.
BiotechHealthtechBoston, US
Francisco J. Quintana(Scientific Founder, Member of Board of Directors)Mark Carthy(Founder and CEO, Member of Board of Directors)
BoardSatish Jindal(Director)
Arch Oncology Incarchoncology.comSeries A · Aug 2016 · $86M
Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot Jain
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.